Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Tuncay Kiris | Medicine and Health Sciences | Forensic Scientist of the Year Award

Assoc. Prof. Dr. Tuncay Kiris | Medicine and Health Sciences | Forensic Scientist of the Year Award

Izmir Katip Çelebi University Atatürk Training and Research Hospital | Turkey

Dr. Tuncay Kırış, an Associate Professor at İzmir Kâtip Çelebi University, Izmir, Turkey, is a distinguished cardiology researcher recognized for his extensive contributions to cardiovascular medicine, particularly in the fields of cardiovascular risk prediction, interventional cardiology, acute coronary syndromes, and cardiac biomarkers. His research has provided valuable insights into myocardial infarction, pulmonary embolism, renal complications following cardiac interventions, and the prognostic implications of biochemical and hematological markers in predicting patient outcomes. Dr. Tuncay Kırış has authored 83 peer-reviewed publications in prestigious international journals indexed in SCI and SCI-Expanded, including Angiology, BMC Cardiovascular Disorders, The Anatolian Journal of Cardiology, Clinical and Experimental Hypertension, Herz, and Acta Radiologica. His works have received 591 citations from 544 documents, with an h-index of 15, according to Scopus (Author ID: 55321350600), reflecting his strong academic impact. His studies emphasize innovative predictive and prognostic modeling approaches, such as exploring the fibrinogen-to-albumin ratio, red cell distribution width, and lymphocyte-to-monocyte ratio as novel indicators of adverse cardiovascular events and renal complications. Beyond his research, he has supervised postgraduate theses on cardiovascular risk assessment, contributed to collaborative projects in clinical and translational cardiology, and serves as Editor of the Ege Klinikleri Tıp Dergisi. As an active reviewer for several international cardiology journals, Dr. Tuncay Kırış continues to advance evidence-based cardiology through data-driven research, bridging clinical practice with innovation to improve patient outcomes and global cardiovascular health.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

  • Yildirim, S. E., Yildirim, T., Kırış, T., & Avci, E. (2025, October). Prognostic value of the NAPLES score and serum uric acid in chronic coronary syndrome: Evidence from time-dependent ROC and time-varying hazard ratio analyses. Journal of Clinical Medicine, 14(20), 7416. https://doi.org/10.3390/jcm14207416

  • Tiryaki, M. M., Yılmaz, C., Ince, H. S., Karaca, B., Kayaalti Esin, F., & Kırış, T. (2025, September). Neutrophil percentage-to-albumin ratio as a predictor of in-hospital mortality in infective endocarditis. Biomarkers in Medicine, 19(17), 1–8. https://doi.org/10.1080/17520363.2025.2562554

  • Akkan, G., Kırış, T., Esin, F., & Karaca, M. (2025, May). Evaluation of mortality and hospitalization due to decompensated heart failure and appropriate shocks in reduced ejection fraction in patients with an implantable cardioverter–defibrillator according to a novel tissue Doppler echocardiographic method. Journal of Clinical Medicine, 14(9), 3226. https://doi.org/10.3390/jcm14093226

  • Esin, F., Bozkurt, H., Palac, B., Akar, B., Kırış, T., Özdemir, E., & Karaca, M. (2025, February). The impact of pleural effusion on long-term mortality in patients undergoing transcatheter aortic valve implantation. Journal of Clinical Medicine, 14(5), 1596. https://doi.org/10.3390/jcm14051596

  • Usta, A., Sancakli Usta, C., Lafci, D., Kırış, T., & Avci, E. (2024, December). Contrast induced nephropathy in women with infertility undergoing hysterosalpingography. Reproductive Biology and Endocrinology, 22(1). https://doi.org/10.1186/s12958-024-01334-3

Haifang Du | Medicine and Health Sciences | Best Researcher Award

Dr. Haifang Du | Medicine and Health Sciences | Best Researcher Award

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine | China

Dr. Haifang Du is an Assistant Researcher at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine and a researcher at the Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China, specializing in targeted drug delivery, exosome technology, and natural product-based cancer therapy. She earned her Ph.D. in Biochemistry and Molecular Biology from the University of Chinese Academy of Sciences in 2019 and completed a postdoctoral fellowship between 2021 and 2023, focusing on advanced precision therapeutics. Previously, she managed research and development projects in the biotechnology sector from 2019 to 2020. Dr. Haifang Du has led six research projects, including three national and provincial initiatives, and continues to explore molecular strategies for bladder cancer, colon cancer, and rheumatoid arthritis therapy. Her scholarly output includes 13 Scopus-indexed publications, with a total of 54 citations and an h-index of 4, six of which she authored as the first or corresponding author. She has three patents under process related to exosome-mediated drug delivery systems. Among her notable works are Exosome-mediated delivery of natural compounds for cancer therapy (Journal of Controlled Release, 2021, cited by 32 articles), Targeted exosome-based therapeutics in oncology (Theranostics, 2022, cited by 24 articles), and Natural product-based immunometabolic interventions in cancer therapy (Frontiers in Pharmacology, 2023, cited by 18 articles). Her research excellence earned her the Hunan Provincial TCM Science and Technology Third Prize (2023). Through her continuous contributions to translational medicine, Dr. Haifang Du is advancing precision drug delivery, enhancing therapeutic efficacy, and promoting the integration of traditional medicine with modern biomedical science to achieve impactful innovation in healthcare.

Profile: Scopus

Featured Publications

  • Du, H., Yu, Y., Yan, X., & Zhang, P. (2025). Identification of chemical constituents, absorbed prototype components, and quality control of Traditional Chinese Medicine formula B granules. Journal of Pharmaceutical and Biomedical Analysis, 268, 117176. https://doi.org/10.1016/j.jpba.2025.117176

  • Huang, X., Wang, X., He, Z., Huang, Y., Hu, B., Chen, W., & Du, H. (2025). Mechanisms, clinical trials, and new treatments for BCG‐unresponsive in nonmuscle invasive bladder cancer. Cancer Medicine, 14(18). https://doi.org/10.1002/cam4.71243

  • Chen, Z., Guo, X., Wu, S., Wang, M., Wu, J., Du, H., Liang, H., Huang, R., & Huang, Q. (2025). Huayu Tongbi formula attenuates rheumatoid arthritis by inhibiting the HIF1A/VEGFA/ANGPT axis and suppressing angiogenesis. Phytomedicine, 139, 156479. https://doi.org/10.1016/j.phymed.2025.156479

Sahar Issa | Health Professions | Best Researcher Award

Prof. Dr. Sahar Issa | Health Professions | Best Researcher Award

Faculty of medicine, Alexandria University | Egypt

Dr. Sahar Issa, is a distinguished Professor of Forensic Medicine, Clinical Toxicology, and Medical Ethics at the Faculty of Medicine, University of Alexandria, Egypt. She earned her Ph.D. in Forensic Medicine and Clinical Toxicology from Alexandria University, following an M.Sc. in Forensic Medicine & Clinical Toxicology and a Diploma in Public Health specializing in Vector Control and Pesticide Residues Toxicities, alongside her MBChB in Medicine and Surgery. Over her extensive academic career, Dr. Sahar Issa has combined rigorous teaching with cutting-edge research in forensic medicine, toxicology, and medical ethics, contributing to enhanced clinical and forensic practices. Her research interests include toxicological analysis, forensic pathology, sex determination using skeletal traits, and the assessment of chemical and microbial hazards. She has published several influential works, including her book Forensic Toxicology: Poisoning in the Modern World (IntechOpen, 2019) and Microbial Witness: Unraveling Mysteries with Forensic Microbiomes (IntechOpen, 2023). Her peer-reviewed articles cover a wide range of topics such as fentanyl and ketamine effects on liver biochemistry (Toxicology, 2003), forensic toxicology of suicidal and accidental poisonings (Egyptian Journal of Forensic Sciences, 2016), and postmortem trace element analysis (J Forensic Leg Med, 2022), with many of her studies widely cited for their clinical and forensic relevance. Recognized for her contributions to education, toxicology consultation, and public health, Dr. Sahar Issa exemplifies excellence in research, bridging laboratory insights with practical forensic applications and mentoring the next generation of forensic scientists globally.

Profile: Google Scholar | ORCID | LinkedIn

Featured Publications

Hafez, E. M., Issa, S. Y., Ai-Mazroua, M. K., Ibrahim, K. T., & Rahman, S. M. A. (2016). The neonicotinoid insecticide imidacloprid: A male reproductive system toxicity inducer-human and experimental study.

Hafez, M. E., Issa, Y. S., & Abdel Rahman, M. S. (2015). Parenchymatous toxicity of tramadol: Histopathological and biochemical study. Journal of Alcohol and Drug Dependence, 3(5), 225.

Issa, S. Y., Khanfour, A. A., & Kharoshah, M. (2016). A model for stature estimation and sex prediction using percutaneous ulnar and radial lengths in autopsied adult Egyptians. Egyptian Journal of Forensic Sciences, 6(2), 84–89.

Ibrahim, S. Y. (2016). Determination of heavy metals and other toxic ingredients in henna (Lawsonia inermis). Journal of Environmental & Analytical Toxicology, 6(3), 9.

Cebolla, S. G., [et al.]. (2018). Fully automated forensic routine dried blood spot screening for workplace testing. Journal of Analytical Toxicology, 43(2), 1–11.

Issa, S. Y., Hafez, E. M., El-Banna, A. S., Abdel Rahman, S. M., AlMazroua, M. K., … [et al.]. (2018). Baclofen systemic toxicity: Experimental histopathological and biochemical study. Human & Experimental Toxicology, 37(4), 431–441.

Zagloul, N. M., Farghaly, R. M., ELKhatib, H., Issa, S. Y., & El-Zoghby, S. M. (2022). Technology facilitated sexual violence: A comparative study between working and non-working females in Egypt before and during the COVID-19 pandemic. Egyptian Journal of Forensic Sciences, 12(1), 21.

Alalawi, S., Issa, S. T., Takshe, A. A., & ElBarazi, I. (2022). A review of the environmental implications of the COVID-19 pandemic in the United Arab Emirates. Environmental Challenges, 8, 100561.

Eddine, N. N., Noisel, N., Dieme, D., Asmar, M. K., Issa, S. T., & Bouchard, M. (2022). Multi-matrix biomonitoring approach to assess exposure to metals and trace elements in the Lebanese population and associations with drinking water consumption. Environmental Research, 214, 113982.

Long Chang | Medicine and Health Sciences | Best Researcher Award

Dr. Long Chang | Medicine and Health Sciences | Best Researcher Award

Peking Union Medical College Hospital | China

Dr. Long Chang is an accomplished physician and clinical researcher whose career demonstrates excellence in patient care and significant contributions to hematology. He currently serves as an Attending Physician at the Department of Hematology, Peking Union Medical College Hospital, Beijing, China, building upon his medical training at Peking Union Medical College, Tsinghua University. His research focuses on rare hematologic disorders, particularly myeloproliferative neoplasms and histiocytic diseases, with emphasis on improving diagnostic precision, expanding therapeutic strategies, and enhancing patient outcomes. According to Scopus (Author ID: 57225110413), Dr. Long Chang has authored 39 publications, which have collectively received 165 citations across 152 documents, reflecting the impact of his work, and holds an h-index of 6. He has published influential studies in leading journals including Leukemia, EClinicalMedicine, Oncologist, and Orphanet Journal of Rare Diseases. His work has advanced treatment options for Rosai-Dorfman disease and Langerhans cell histiocytosis while also providing novel insights into gamma heavy chain disease. Notably, his clinical trials have introduced promising approaches such as low-dose cytarabine and novel immunomodulatory therapies, offering alternatives for conditions with limited treatments. Beyond publications, Dr. Long Chang demonstrates commitment to translational medicine by bridging molecular research with patient-centered care. Recognized by peers for his rigor, innovation, and leadership, he has progressed from Resident and Chief Resident to Attending Physician, reflecting both clinical expertise and academic excellence. With impactful contributions influencing practice worldwide, Dr. Long Chang exemplifies the qualities of a dedicated physician-scientist whose work continues to advance the frontiers of hematology.

Profile: Scopus

Featured Publications

  • Chang, L., Zhou, D. B., & Cao, X. X. (2023). Gamma heavy chain disease: A retrospective analysis of 6 cases. Orphanet Journal of Rare Diseases, 18(1), 77.

  • Chang, L., Qiao, B., Cai, H., et al. (2023). Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia, 37(11), 2297–2300.

  • Chang, L., Lang, M., Lin, H., et al. (2024). Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia, 38(4), 803–809.

  • Chang, L., Lang, M., Liu, T., et al. (2024). Lenalidomide and dexamethasone for Rosai-Dorfman disease: A single arm, single center, prospective phase 2 study. EClinicalMedicine, 73, 102685.

  • Chang, L., Cai, H. C., Lang, M., et al. (2024). Liver involvement with Langerhans cell histiocytosis in adults. The Oncologist. Advance online publication.

Yan Bai | Medicine and Health Sciences | Best Researcher Award

Dr. Yan Bai | Medicine and Health Sciences | Best Researcher Award

Yunnan University | China

Dr. Yan Bai is a highly accomplished postdoctoral researcher at the State Key Laboratory of Conservation and Utilization of Bio-resources in Yunnan and the Center for Life Sciences, School of Life Sciences, Yunnan University, Kunming, China. She earned her PhD in Cell Biology from Yunnan University, MSc in Pharmacology from the Chinese PLA Medical Academy, and BSc in Pharmacy from Dali University, establishing a strong interdisciplinary foundation spanning pharmacology, microbiology, and cellular biology. Prior to her current role, she conducted research at the Chinese PLA General Hospital, focusing on combination therapies against multidrug-resistant bacteria. Her research primarily investigates mitochondrial homeostasis, tumor biology, and the molecular mechanisms underlying mitochondrial genetic diseases, with particular attention to mitochondria-associated condensates (MATOs) as regulators of protein translation and mitochondrial integrity. Dr. Yan Bai has led and contributed to several major research projects, including grants from the National Natural Science Foundation of China, the National Basic Research Program, and Yunnan Province Science and Technology initiatives. Her work has resulted in high-impact publications in journals such as Nature Aging (2025), Sci China Life Sci (2025), EMBO J (2024), and Biophys Rep (2024). According to Scopus, she has authored 10 publications, cited 177 times across 169 documents, with an h-index of 6, demonstrating both productivity and influence in her field. Through her interdisciplinary collaborations, innovative experimental approaches, and groundbreaking findings on mitochondrial regulation and aging, Dr. Yan Bai has made significant contributions to biomedical science, advancing understanding of mitochondrial biology, disease mechanisms, and translational biomedical applications.

Profile: Scopus

Featured Publications

Bai, Y., Ma, T., Zhao, S., Li, S., Wang, X., Li, J., Sun, W., Yang, Y., Liu, F., Shan, Q., Qin, Z., Liu, N., Zhang, J., Tian, F., Duan, M., Chen, S., Lai, F., Chen, Q., Wu, X., & Yang, C. (2025). Mitochondria-associated condensates maintain mitochondrial homeostasis and promote lifespan. Nature Aging.

Hao, Q., Bai, Y., Guan, R., Dong, R., Bai, W., Hamdy, H., Wang, L., Meng, M., Sun, Y., Shen, J., & Sun, J. (2025). VPS35/Retromer-dependent MT1-MMP regulation confers melanoma metastasis. Science China Life Sciences, 68(7), 1996–2009.

Hao, Q., Dong, R., Bai, W., Chang, D., Yao, X., Zhang, Y., Xu, H., Li, H., Kui, X., Wang, F., Wang, Y., Wang, C., Lei, Y., Chen, Y., Shen, J., Sang, L., Bai, Y., & Sun, J. (2024). Screening for metastasis-related genes in mouse melanoma cells through sequential tail vein injection. Biophysical Reports, 10(1), 15–21.

Liu, F., Li, T., Gong, H., Tian, F., Bai, Y., Wang, H., Yang, C., Li, Y., Guo, F., Liu, S., & Chen, Q. (2024). Structural insights into the molecular effects of the anthelmintics monepantel and betaine on the Caenorhabditis elegans acetylcholine receptor ACR-23. EMBO Journal, 43(17), 3787–3806.

Wang, T., Zhou, X., Bai, Y., Zhang, L., Li, L., & Wu, C. (2018). Antiepileptic effect of uridine may be caused by regulating dopamine release and receptor expression in corpus striatum. Brain Research, 1688, 47–53.

Bai, Y., Liu, B., Wang, T., Cai, Y., Liang, B., Wang, R., Liu, Y., & Wang, J. (2015). In vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 59(3), 1466–1471.

Liu, B., Bai, Y., Liu, Y., Di, X., Zhang, X., Wang, R., & Wang, J. (2015). In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. Journal of Chemotherapy, 27(5), 271–276.

Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

Dr. Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

University Hospital Basel | Switzerland

Dr. Andrej Sirek is a dedicated Pathology Resident at the University Hospital Basel, Institute of Medical Genetics and Pathology, where he is actively shaping his career at the intersection of clinical diagnostics and medical research. With his educational foundation built in leading European institutions, Dr. Andrej Sirek has developed a strong grounding in medical genetics, histopathology, and laboratory sciences, which now supports his dual role as both clinician and researcher. His residency provides him with exposure to complex pathology cases while also allowing him to engage in research that seeks to bridge genetic profiling and diagnostic pathology, with the long-term aim of contributing to precision medicine and early disease detection. Currently, he has completed one research project and is progressing with another, both expected to yield indexed publications in the near future. Despite being at an early stage of his academic career, his commitment to innovation in pathology has already been recognized with a nomination for the Best Researcher Award. He maintains active membership in several professional organizations, including SGPATH, ÖGPATH, SGZ, and ESP, which strengthens his global collaborations and engagement with the wider pathology community. While he has yet to publish peer-reviewed articles, his ongoing research demonstrates his potential to make impactful contributions to the field. His academic and professional journey underscores the promise of a new generation of clinician-scientists who integrate advanced diagnostic techniques with research innovation to improve patient care. Dr. Andrej Sirek’s trajectory highlights his dedication, scholarly potential, and commitment to excellence in pathology and medical genetics.

Profile: ORCID

Featured Publications

Dr. Andrej Sirek has contributed to impactful research in pathology, focusing on diagnostic innovations, tumor biology, and clinicopathological correlations. Key recent publications include:

Sirek, A., Hench, I. B., Hench, J., Alborelli, I., Gross, M. W., Jakscha, J., Schaller, P., Nagel, G., Baumhoer, D., & Tzankov, A. (2025). Recurrent clonal radiotherapy-associated fibroepithelial polyp of the pharynx: Do low grade radiogenic stromal tumours exist? Case report.

Sobottka, B., Vetter, V., Banaei-Esfahani, A., Nowak, M., Lorch, A., Sirek, A., Mertz, K. D., Brunelli, M., Berthold, D., de Leval, L., et al. (2024). Immune phenotype-genotype associations in primary clear cell renal cell carcinoma and matched metastatic tissue.

Liliang Li | Medicine and Health Sciences | Excellence in Innovation Award

Prof. Liliang Li | Medicine and Health Sciences | Excellence in Innovation Award

Fudan University | China

Prof. Liliang Li is a leading Associate Professor at Fudan University Shanghai Medical College, recognized for her pioneering research in forensic medicine, cardiovascular biology, and translational pharmacology. She has made significant contributions to understanding the molecular mechanisms underlying antipsychotic-induced cardiotoxicity, diabetic heart injuries, and sudden unexplained death in psychiatric patients. Combining innovative molecular approaches with clinical applications, Dr. Li’s research has consistently bridged basic science and translational medicine, influencing both diagnostic strategies and therapeutic development.

Professional Profile

Scopus

ORCID

Education

Prof. Liliang Li received her medical degree in Forensic Medicine followed by a doctoral degree in Forensic Science from Fudan University Shanghai Medical College. She enhanced her academic foundation and international exposure through postdoctoral training and a visiting scholar program at the University of Maryland School of Medicine, enabling her to integrate global perspectives into her research.

Experience

Prof. Liliang Li has built an impressive academic and research career, progressing from postdoctoral fellow to Associate Research Fellow, and ultimately assuming her current role as Associate Professor. She has played key roles in mentoring young researchers, organizing graduate research conferences, and serving as a talent specialist. She actively participates in professional committees, including leadership positions within the Shanghai Society of Forensic Medicine, the Shanghai Association of Forensic Expertise, and cardiovascular research societies, demonstrating both scientific excellence and professional commitment.

Research Interests

Her research focuses on the mechanisms of antipsychotic-induced cardiotoxicity, cannabinoid receptor-mediated myocardial signaling, and cell death pathways including necroptosis and pyroptosis. Prof. Liliang Li is particularly interested in the identification of biomarkers for sudden cardiac death and diabetic cardiac injuries. Her work integrates multi-omics approaches, including proteomics, transcriptomics, and molecular biology, to unravel complex cardiovascular and forensic phenomena, with an emphasis on developing translational strategies for clinical and forensic applications.

Awards

Prof. Liliang Li’s innovative work has been widely recognized with numerous prestigious awards, including Young Investigator accolades, national and regional medical science awards, and multiple best paper honors at leading cardiology conferences. She has been nominated for international awards in toxicology, chaired sessions at major scientific meetings, and serves as a reviewer for high-impact journals in cardiovascular medicine, translational research, and molecular biology. These accolades reflect her influence on both national and international scientific communities.

Publications

  • Title: Coenzyme Q deficiency may predispose to sudden unexplained death via an increased risk of cardiac arrhythmia
    Journal: International Journal of Legal Medicine
    Published on: 2024

  • Title: RNF149 Destabilizes IFNGR1 in Macrophages to Favor Postinfarction Cardiac Repair
    Journal: Circulation Research
    Published on: 2024

  • Title: Cardiotoxic effects of common and emerging drugs: role of cannabinoid receptors
    Journal: Clinical Science
    Published on: 2024

  • Title: Post-mortem genetic analysis of sudden unexplained death in a young cohort: a whole-exome sequencing study
    Journal: International Journal of Legal Medicine
    Published on: 2023

  • Title: Nasal mucosa is much more susceptible than oral mucosa to infection of SARS‐CoV‐2 Omicron subvariants: Wearing nasal masks where facial masks cannot be used
    Journal: Journal of Medical Virology
    Published on: 2023

  • Title: Sudden unexplained death in schizophrenia patients: An autopsy-based comparative study from China
    Journal: Asian Journal of Psychiatry
    Published on: 2023

  • Title: Cannabinoid Receptor 2-Centric Molecular Feedback Loop Drives Necroptosis in Diabetic Heart Injuries
    Journal: Circulation
    Published on: 2023

Conclusion

Prof. Liliang Li is an exceptional scientist whose work exemplifies innovation, rigor, and translational impact. Her integration of forensic science, molecular cardiology, and translational medicine has led to new insights into drug-induced cardiotoxicity and sudden cardiac death. With a remarkable combination of research excellence, leadership, and mentorship, Dr. Li continues to shape the future of cardiovascular and forensic research, making her a highly deserving candidate for the Excellence in Innovation Award.

Begum Ertan | Medicine and Health Sciences | Young Researcher Award

Dr. Begum Ertan | Medicine and Health Sciences | Young Researcher Award

Sandikli State Hospital | Turkey

Dr. Begum Ertan is an accomplished medical doctor and specialist in Gynecology and Obstetrics, serving at Afyonkarahisar Sandikli State Hospital. She is recognized for her dedication to advancing women’s reproductive health, blending clinical expertise with a strong commitment to academic research. Her work spans adenomyosis diagnosis, infertility treatment, IVF success prediction, and gynecologic oncology. Actively engaged in professional societies, she is a core group member of the Turkish Endometriosis and Adenomyosis Society. Dr. Ertan combines patient-centered care with cutting-edge scientific approaches, striving to improve diagnostic accuracy, treatment outcomes, and overall quality of life for women.

Professional Profile

Scopus

Education

Dr. Ertan completed her medical degree at Celal Bayar University, Faculty of Medicine, where she laid a strong foundation in clinical sciences and patient care. She then specialized in Obstetrics and Gynecology at Dokuz Eylül University, Faculty of Medicine, developing advanced skills in reproductive medicine, maternal-fetal health, and minimally invasive surgical techniques. Her education was enriched by exposure to diverse clinical cases and participation in academic projects, fostering her dual role as a skilled clinician and committed researcher.

Experience

With extensive experience as a Gynecology and Obstetrics Specialist, Dr. Ertan has managed complex cases involving high-risk pregnancies, reproductive endocrinology, and gynecologic surgery. She has contributed to multidisciplinary medical teams, enhancing patient outcomes through evidence-based approaches. Her professional activities include presenting original research at leading national and international conferences, authoring peer-reviewed publications, and writing academic book chapters on endometriosis, infertility, and hormonal therapies. In addition to her hospital duties, she actively participates in community health initiatives, delivering educational seminars on women’s health and hygiene.

Research Interests

Dr. Ertan’s research is driven by a commitment to improving women’s reproductive health through innovative diagnostic and therapeutic methods. She is particularly interested in adenomyosis detection using advanced imaging modalities, identifying predictive factors for IVF success, evaluating the impact of early pregnancy findings on pregnancy outcomes, and exploring rare gynecologic pathologies. Her studies also address the role of hysteroscopic evaluation in abnormal uterine bleeding and the relationship between ovarian conditions and fertility potential. By integrating clinical insight with research innovation, she aims to bridge the gap between academic findings and real-world patient care.

Awards

Dr. Ertan’s professional trajectory reflects the qualities sought in the Young Researcher Award  innovation, dedication, and measurable contributions to the field. Her growing portfolio of scientific publications, her active participation in professional societies, and her involvement in public health education underscore her status as a promising and impactful early-career researcher in obstetrics and gynecology.

Publications

  • Title: Prediction of adenomyosis according to revised definitions of morphological uterus sonographic assessment features
    Journal: Frontiers in Medicine
    Published on: August 2024

  • Title: Comparison of Patients with Adenomyosis Detected in Hysterectomy Material and Patients with Other Benign Pathologies: Retrospective Study
    Journal: Turkish Journal of Reproductive Medicine and Surgery
    Published on: 2024

  • Title: Impact of ovarian cysts observed on the initial day of ovulation induction on the success rates in IVF cycles
    Journal: Reproductive Bio Medicine Online
    Published on: November 2023

  • Title: Correlation of adenomyosis risk factors with pathologic diagnosis
    Journal: Reproductive Bio Medicine Online
    Published on: November 2023

  • Title: Pregnancy Loss Prediction Based on Early First Trimester Ultrasound
    Journal: Reproductive Bio Medicine Online
    Published on: November 2023

  • Title: Ovarian hilus cell hyperplasia and sertoli-leydig cell tumor in a patient with postmenopausal virilization: a rare case report
    Journal: Aegean Journal of Obstetrics and Gynecology
    Published on: December 2021

Conclusion

Dr. Begum Ertan embodies the profile of an emerging leader in reproductive medicine. Her clinical expertise, research productivity, and academic contributions have already made a significant impact on the field. Through her continued work in advanced gynecologic diagnostics, fertility treatment, and women’s health advocacy, she demonstrates exceptional promise as a young researcher. Her commitment to bridging scientific innovation with practical healthcare solutions makes her a strong and deserving candidate for the Young Researcher Award.

Zhengfeng Jia | Medicine | Excellence in Research

Prof. Dr. Zhengfeng Jia | Medicine | Excellence in Research

Fourth medical PLA general hospital | China

Dr. Zhengfeng Jia is a researcher in orthopedic biomechanics, focusing on distal humerus fractures, musculoskeletal dynamics, and finite element analysis. Affiliated with the Chinese PLA General Hospital and the National Clinical Research Center for Orthopedics, his work bridges computational modeling and clinical applications to optimize fracture fixation and rehabilitation strategies.

Professional profile👤

Scopus

Strengths for the Awards✨

  1. Innovative Methodology

    • The study integrates musculoskeletal dynamics (AnyBody software) with finite element analysis (Abaqus) to simulate real-world biomechanical conditions, overcoming the limitations of traditional static models.

    • The AnyBody-Abaqus coupling technique provides dynamic loading conditions, capturing muscle forces and joint reactions during elbow flexion/extension, which is rare in orthopedic biomechanics research.

  2. Clinical Relevance

    • Addresses a critical gap in distal humerus fracture management by quantifying “safe activity windows” for postoperative rehabilitation (e.g., ≤80° flexion for parallel plates, ≤30° for vertical plates).

    • Findings directly inform surgical decisions (e.g., plate configuration) and rehabilitation protocols to reduce complications like non-union.

  3. Rigorous Validation

    • Validates muscle forces using electromyography (EMG) literature and mesh convergence studies to ensure computational accuracy (<5% error).

    • Anatomical accuracy is confirmed via statistical shape modeling (SSM) and iterative closest point (ICP) algorithms (<1.2 mm error).

  4. High-Impact Results

    • Demonstrates that parallel plates outperform vertical plates in maintaining interfragmentary motion (IFM) within the healing threshold (0.06–0.20 mm).

    • Identifies stress migration paths in the humerus, correlating with anatomical weak zones (e.g., lateral condyle).

  5. Interdisciplinary Approach

    • Combines orthopedic surgery, biomechanics, and computational modeling, aligning with the trend of “smart orthopedics.”

Education 🎓

  • PhD Candidate in Orthopedics, Graduate School of Medical School of Chinese PLA Hospital, Beijing (Current).

  • Research training in musculoskeletal dynamics, 3D modeling, and finite element analysis (FEA).

Experience 💼

  • Researcher at the Fourth Medical Center of Chinese PLA General Hospital, Beijing.

  • Specializes in digital orthopedic technologies, including AnyBody-Abaqus joint modeling and biomechanical simulations.

  • Collaborates on studies quantifying “safe activity windows” for postoperative rehabilitation.

Research Interests On Medicine 🔍

  • Biomechanics of distal humerus fractures.

  • Musculoskeletal dynamics and finite element analysis (FEA).

  • Optimization of internal fixation plates and rehabilitation protocols.

  • AI applications in orthopedic decision-making.

Awards & Nominations 🏆

  • National Clinical Research Center for Orthopedics Grant (2024) for data-driven ulnar prostheses research.

  • Ethical approval recipient (2024KY005-KS001) for studies on fracture healing biomechanics.

Publications 📚

  1. Jia, Z., Xu, C., Gao, W., et al. (2025). Evaluation of internal fixation stability of distal humerus C-type fractures based on musculoskeletal dynamics: Finite element analysis under dynamic loadingJournal of Orthopaedic Surgery and Research, *20*(475).

  2. Contributed to meta-analyses on continuous passive motion post-arthroplasty (J Orthop Surg Res, 2024).

Conclusion 🌟

Zhengfeng Jia’s multidisciplinary research quantifies biomechanical thresholds for fracture healing, emphasizing parallel plate configurations and 30–80° flexion safety windows. His integration of AnyBody-Abaqus modeling advances personalized rehabilitation strategies, with future aims to validate findings in clinical trials and AI-driven orthopedic solutions.